Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

LSD1 inhibitor

DRUG CLASS:

LSD1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	SP2577 Sensitive: B - Late Trials SP2577 Sensitive : B	SP2577 Sensitive: B - Late Trials SP2577 Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	ORY-1001 Sensitive: C2 – Inclusion Criteria ORY-1001 Sensitive : C2	ORY-1001 Sensitive: C2 – Inclusion Criteria ORY-1001 Sensitive : C2
TAF15-CHN1 translocation	Osteosarcoma	TAF15-CHN1 translocation	Osteosarcoma	SP2577 Sensitive: C3 – Early Trials SP2577 Sensitive : C3	SP2577 Sensitive: C3 – Early Trials SP2577 Sensitive : C3
FUS-DDIT3 translocation	Liposarcoma	FUS-DDIT3 translocation	Liposarcoma	SP2577 Sensitive: C3 – Early Trials SP2577 Sensitive : C3	SP2577 Sensitive: C3 – Early Trials SP2577 Sensitive : C3
IFNG gene signature overexpression	Melanoma	IFNG gene signature overexpression	Melanoma	nivolumab + 4SC-202 Sensitive: C3 – Early Trials nivolumab + 4SC-202 Sensitive : C3	nivolumab + 4SC-202 Sensitive: C3 – Early Trials nivolumab + 4SC-202 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	ORY-1001 Sensitive: C3 – Early Trials ORY-1001 Sensitive : C3	ORY-1001 Sensitive: C3 – Early Trials ORY-1001 Sensitive : C3
SMARCA4 mutation	Ovarian Cancer	SMARCA4 mutation	Ovarian Cancer	SP2577 Sensitive: C4 – Case Studies SP2577 Sensitive : C4	SP2577 Sensitive: C4 – Case Studies SP2577 Sensitive : C4
JAK2 V617F	Acute Myelogenous Leukemia	JAK2 V617F	Acute Myelogenous Leukemia	CPI-482 Sensitive: D – Preclinical CPI-482 Sensitive : D	CPI-482 Sensitive: D – Preclinical CPI-482 Sensitive : D
MCL1 overexpression	Acute Myelogenous Leukemia	MCL1 overexpression	Acute Myelogenous Leukemia	venetoclax + INCB59872 Sensitive: D – Preclinical venetoclax + INCB59872 Sensitive : D	venetoclax + INCB59872 Sensitive: D – Preclinical venetoclax + INCB59872 Sensitive : D
KDM1A overexpression	Acute Myelogenous Leukemia	KDM1A overexpression	Acute Myelogenous Leukemia	LSD1 inhibitor + ruxolitinib Sensitive: D – Preclinical LSD1 inhibitor + ruxolitinib Sensitive : D	LSD1 inhibitor + ruxolitinib Sensitive: D – Preclinical LSD1 inhibitor + ruxolitinib Sensitive : D
KDM1A overexpression	Osteosarcoma	KDM1A overexpression	Osteosarcoma	SP2577 Sensitive: D – Preclinical SP2577 Sensitive : D	SP2577 Sensitive: D – Preclinical SP2577 Sensitive : D
KDM1A overexpression	Rhabdomyosarcoma	KDM1A overexpression	Rhabdomyosarcoma	SP2577 Sensitive: D – Preclinical SP2577 Sensitive : D	SP2577 Sensitive: D – Preclinical SP2577 Sensitive : D
KDM1A overexpression	Ewing Sarcoma	KDM1A overexpression	Ewing Sarcoma	SP2577 Sensitive: D – Preclinical SP2577 Sensitive : D	SP2577 Sensitive: D – Preclinical SP2577 Sensitive : D
PTPRC positive	Acute Myelogenous Leukemia	PTPRC positive	Acute Myelogenous Leukemia	venetoclax + MK-3543 Sensitive: D – Preclinical venetoclax + MK-3543 Sensitive : D	venetoclax + MK-3543 Sensitive: D – Preclinical venetoclax + MK-3543 Sensitive : D
MLL-AF4 fusion	Acute Myelogenous Leukemia	MLL-AF4 fusion	Acute Myelogenous Leukemia	revumenib + ORY-1001 Sensitive: D – Preclinical revumenib + ORY-1001 Sensitive : D	revumenib + ORY-1001 Sensitive: D – Preclinical revumenib + ORY-1001 Sensitive : D
MLL rearrangement	Acute Myelogenous Leukemia	MLL rearrangement	Acute Myelogenous Leukemia	revumenib + ORY-1001 Sensitive: D – Preclinical revumenib + ORY-1001 Sensitive : D	revumenib + ORY-1001 Sensitive: D – Preclinical revumenib + ORY-1001 Sensitive : D
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	revumenib + ORY-1001 Sensitive: D – Preclinical revumenib + ORY-1001 Sensitive : D	revumenib + ORY-1001 Sensitive: D – Preclinical revumenib + ORY-1001 Sensitive : D